CD274 and neoplasm: Although no significant difference was observed in PD-L1 expression by tumor cells between B3/C and non-B3/C, the effects of nivolumab on T-cell cytotoxicity were stronger in patients with high expression levels of PD-L1 in B3/C (Supplementary Table S2 and Supplementary Fig. S9).